Prairie Plant Systems and CanniMed Granted Section 56 Exemptions to Begin Cannabis Oils Production
SASKATOON, Aug. 6, 2015 /CNW/ – Prairie Plant Systems Inc. and CanniMed Ltd. have successfully received Section 56 exemptions under the Marihuana for Medical Purposes Regulations (MMPR) governed by Health Canada and as a result have begun oil manufacturing for patients.
Similar to the seven dry cannabis products currently being offered, CanniMed® oils will be available in three distinct THC-to-CBD ratios:
- CanniMed® oil 18:0 – containing 18.3 mg/ml THC and 0.2 mg/ml CBD
- CanniMed® oil 10:10 – containing 9.7 mg/ml THC and 10.3 mg/ml CBD
- CanniMed® oil 1:20 – containing 1.2 mg/ml THC and 20.5 mg/ml CBD
“We are very proud to be among the first licensed producers to receive the go ahead from Health Canada to manufacture CanniMed oils for our patients,” said Brent Zettl, President and CEO of Prairie Plant Systems Inc. and CanniMed Ltd. “Patient requests for oils have been significant with as many as 67 per cent responding to an informal survey suggesting they would prefer this delivery method over smoking or vaporizing.”
CanniMed® oil will be packaged in 60 ml bottles and include an oral syringe for consistent dosing and as a spill prevention.
About CanniMed and Prairie Plant Systems
CanniMed Ltd. was the first producer to be licensed under the Marihuana for Medical Purposes Regulations (MMPR). Our pharmaceutical-grade cannabis is produced under Good Manufacturing Practices (GMP) regulations, the criteria used to manufacture all pharmaceuticals in Canada. Our primary focus is on patient safety, undertaken by strictly following a 281 point quality control process.
CanniMed’s parent company, Prairie Plant Systems Inc. was the sole supplier to Health Canada under the former medical marijuana system for 13 years, and has been producing safe and consistent medical marijuana for thousands of Canadian patients, with no incident of diversion.
These two companies together have created the leading medical cannabis company in Canada with a strong corporate priority to design and execute clinical research that will close the gap between the anecdotal benefit and evidence based medicine in order to standardize care. Our Canadian-grown cannabis is already leading the way in standardizing care and has been used in a published clinical trial demonstrating the efficacy of smoked cannabis for chronic pain,1 which was used in the development of the Canadian Pain Society’s Pharmacological management of chronic neuropathic pain: Revised consensus statement positioning medical cannabis as third line treatment for neuropathic pain.2
1 Ware, M.A., Wang, T., Shapiro, S., Robinson, A. and others. (2010) Smoked Cannabis for Chronic Pain: a Randomized Controlled Trial. Canadian Medical Association Journal (CMAJ). 182:E694-E701.
2 Moulin, D.E., Boulanger, A., Clark A.J., Dao, T. and others. (2014) Pharmacological Management of Chronic Neuropathic Pain: Revised Consensus Statement from the Canadian Pain Society. Pain Research and Management. Nov-Dec; 19(6): 328-335.
For further information:
Dara Willis Communications